A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Vorolanib (Primary) ; Everolimus
- Indications Adenocarcinoma; Cholangiocarcinoma; Glioblastoma; Liver cancer; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 18 Mar 2021 Results assessing the Dose limiting toxicities and recommended phase 2 dose of Vorolanib published in the Investigational New Drugs
- 27 Aug 2020 Status changed from active, no longer recruiting to discontinued.
- 04 Jun 2020 Planned End Date changed from 30 Jun 2020 to 30 Sep 2023.